Key statistics
On Thursday, Black Diamond Therapeutics Inc (BDTX:NSQ) closed at 2.43, 13.29% above the 52 week low of 2.15 set on Nov 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.44 |
---|---|
High | 2.47 |
Low | 2.31 |
Bid | 2.37 |
Offer | 2.55 |
Previous close | 2.43 |
Average volume | 458.49k |
---|---|
Shares outstanding | 56.59m |
Free float | 55.31m |
P/E (TTM) | -- |
Market cap | 137.50m USD |
EPS (TTM) | -1.36 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
- Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
- Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
- Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
- Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
- Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
- Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
More ▼